Kidney flow and function in hypertension: Protective effects of pycnogenol in hypertensive participants-a controlled study

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 41-46

  Cesarone, Maria Rosaria ^a   Belcaro, Gianni ^a   Stuard, Stefano ^a   Scḧnlau, Frank ^a   Di Renzo, Andrea ^a   Grossi, Maria Giovanna ^a   Dugall, Mark ^a   Cornelli, Umberto ^a   Cacchio, Marisa ^a   Gizzi, Giuseppe ^a   Pellegrini, Luciano ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Hypertension; Kidney flow; Pycnogenol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; PYCNOGENOL; RAMIPRIL;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; FLOW RATE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART RATE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FUNCTION; LEUKOCYTE COUNT; MALE; MICROALBUMINURIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; FLAVONOIDS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RAMIPRIL; TREATMENT OUTCOME;

EID: 76749095167     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409356063     Document Type: Article

References (35)

1. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002 ; 40 (4). 158-168.
2. Ryan J., Croft K., Mori T., et al. An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol. 2008 ; 22 (5). 553-562.
3. Belcaro G., Cesarone MR, Ricci A., et al. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost. 2006 ; 12 (4). 440-444.
4. ®). J Inflamm. 2006 ; 3: 1-15.
5. ®. Thromb Res. 1999 ; 95 (4). 155-161.
6. ® and cardiovascular health. Review. Evidence Based Integr Med. 2003 ; 1 (1). 27-32.
7. ®, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007 ; 30 (9). 775-780.
8. ® in modifying blood pressure in mildly hypertensive patients. Nutr Res. 2001 ; 21 (9). 67-76.
9. Liu X., Wei J., Tan F., Zhou S., Ẅrthwein G., Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004 ; 2 ; 74 (7). 855-862. (Pubitemid 37501134)
10. Zibadi S., Rohdewald PJ, Park D., Watson RR Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008 ; 28 (5). 315-320.
11. Cesarone MR, Belcaro G. Variations in kidney cortical flow with Pycnogenol treatment. A preliminar observational study. Angiology on line. 2008 ; 01: 1-3.
12. Cesarone MR, Laurora G., Belcaro GV Microcirculation in systemic hypertension. Angiology. 1992 ; 43 (11). 899-903.
13. Belcaro G., Cesarone MR, De Sanctis MT, Cornelli U. Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. Int Angiol. 2001 ; 20 (2). 136-139.
14. Belcaro G., Nicolaides AN, Cesarone MR, et al. Vascular screening in andropause: non-invasive investigations in vascular disease screening. Curr Med Res Opin. 2000 ; 16 (suppl 1). s68 - s71.
15. Cesarone MR, Incandela L., Ledda A., et al. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology. 2000 ; 51 (8 pt 2). S53 - S63.
16. Belcaro G., Cesarone MR, Ricci A., et al. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost. 2006 ; 12 (4). 440-444.
17. Steigerwalt RD Jr, Belcaro GV, Laurora G., Cesarone MR, De Sanctis MT Ocular and orbital blood flow in patients with essential hypertension treated with trandolapril. Retina. 1998 ; 18 (6). 539-545.
18. Incandela L., Belcaro G., Nicolaides AN, Laurora G., Cesarone MR, De Sanctis MT Laser-Doppler flux in the normal and atherosclerotic carotid artery wall in normotensive and hypertensive subjects. Panminerva Med. 1996 ; 38 (4). 203-206.
19. Belcaro G., Cesarone MR, Stuard S. Noninvasive cortical kidney flow measurements with Doppler in normal subjects and in hypertensives. Methods and Variability. Angiology on Line. 2009 ; 1: 3-4.
20. Robles NR, Mena C., Velasco J., et al. MICREX study investigators. Microalbuminuria-related cardiovascular risk in diabetic patients and hypertensive (non diabetic) population] Med Clin (Barc). 2008 23 ; 130 (6). 206-209.
21. No author listed. Renal failure as a factor of vascular aging. Ter Arkh. 2007 ; 79 (6). 49-52.
22. Roberto Robles N., Velasco J., Mena C., Angulo E., Garrote T. MICREX Study. Microalbuminuria in diabetic and hypertensive patients: a study of 979 patients. Med Clin (Barc). 2006 ; 127 (20). 761-764.
23. Tripathi G., Dharmani P., Khan F., Sharma RK, Pandirikkal V., Agrawal S. High prevalence of ACE DD genotype among north Indian end stage renal disease patients. BMC Nephrol. 2006 ; 7: 15-21.
24. Frimat L., Siewe G., Loos-Ayav C., Brianon S., Kessler M., Aubrège A. Chronic kidney disease: do generalists and nephrologists differ in their care? Nephrol Ther. 2006 ; 2 (3). 127-135. Epub 2006 Jun 21.
25. Kutyrina IM, Rudenko TE, Shvetsov MIu, Kushnir VV Risk factors of vascular complications in patients at a predialysis stage of chronic renal failure. Ter Arkh. 2006 ; 78 (5). 45-50.
26. Reddy P., Mooradian AD Diuretics: an update on the pharmacology and clinical uses. Am J Ther. 2009 [Epub ahead of print].
27. Yuliana ND, Khatib A., Link-Struensee AM, et al. Adenosine A1 Receptor Binding Activity of Methoxy Flavonoids from Orthosiphon stamineus. Planta Med. 2009 [Epub ahead of print].
28. Konno Y., Kimura K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J. 2008 ; 49 (6). 723-732.
29. No authors listed. Ischemic renal disease (atherosclerotic renovascular hypertension), a clinical variant of disseminated atherosclerosis and a cause of chronic renal insufficiency. Vestn Ross Akad Med Nauk. 2008 ;(11). 24-33.
30. Gobe G. Identification of apoptosis in kidney tissue sections. Methods Mol Biol. 2009 ; 466: 1-18.
31. Krzych LJ, Szydlowski L. Determinants of inappropriate circadian blood pressure variability in children with essential hypertension. Can J Cardiol. 2009 ; 25 (1). e13 - e16.
32. No authors listed. Chronotherapy and relativity theory. Lik Sprava. 2008 ;(3-4). 113-122.
33. liveira MG, Noblat AC, Noblat L., Passos LC Analysis of the prescription of captopril to hospitalized patients. Arq Bras Cardiol. 2008 ; 91 (6). 383-384.
34. Alcázar Arroyo R., Orte Martínez L., Otero González A. Advanced chronic kidney disease. Nefrologia. 2008 ; 28 (suppl 3). 3-6.
35. Swales JD, Sever P. Hypertension. London: Gower Medical Publishing ; 2001.